Landmark test result for surface sanitiser validates 24 hour residual efficacy against Coronavirus

  • Product first to have solid evidence of real success in frequent-use areas against viruses – 99.9% reduction after 24 hours
  • News comes as millions of businesses and public spaces prepare to reopen over the next few months
  • Test data provides assurance to organisations aiming to welcome back customers, students, visitors and employees

The Byotrol PLC technical team has successfully developed a test method to verify whether a disinfectant will provide long-lasting protection against viruses in ‘real-life’ conditions, infection prevention company Byotrol plc, announced that its 4-in-1 Multi-purpose Cleaner and Disinfectant has successfully passed the test confirming COVID-19 protection on frequently touched hard surfaces over 24-hours.

It’s the first time that users can have confidence that the disinfectant they have purchased will provide 24-hour protection against coronavirus on frequently-touched hard surfaces in public spaces - from handrails and door handles to worktops, chairs and other areas such as lifts, office environments and hospitality areas.

The new test standard was developed to replicate in-use conditions rather than the perfect laboratory environment typically used in such tests and makes this a significant step forward for the testing of disinfectant products in the future. Byotrol plc, which developed and performed the new test, has a team of virologists and microbiologists who have worked on the project over several months, to ensure that the data is robust, resulting in Byotrol declaring that its 4-in-1 Multi-Purpose Cleaner & Disinfectant is proven to protect against coronavirus on hard surfaces for 24-hours after application.

Professor James Stewart, Chair of Molecular Virology at the University of Liverpool reviewed and verified the results externally. Professor Stewart was keen to comment on what the result means for the future of disinfectants: “The protocol used to generate the data that supports the 24-hour anti-viral claim is scientifically sound.. I have reviewed the report that describes the execution of this test, the data generated and the result obtained on Byotrol’s 4-in-1 product and I can validate the result of a 3.35 Log reduction of this product relative to the water control

In 2014, Byotrol’s technical team, with the help of independent industry experts, established the BSI approved PAS 2424:2014 method for confirming long-lasting protection of disinfectants against bacteria. The PAS 2424:2014 test is currently being reviewed by the CEN Committee for approval as a new European EN test standard.

Whilst other disinfectant manufacturers have claimed long-lasting protection against Coronavirus over the course of the pandemic, this is the first time the claim has been supported by such rigorous test data, performed to a long-lasting test method against a relevant virus – and crucially, using abrasion to mimic the ‘real-life’ conditions of the product in-use.

Byotrol’s 4-in-1’ is fast-acting, it kills 99.99% of bacteria and viruses and offers long-lasting antimicrobial protection for up to 24 hours, even in frequently touched areas. The formula contains the ActizoneTM polymer technology from Solvay, which anchors antimicrobial actives to the surface enabling the residual antimicrobial nature of the formulation. ActizoneTM technology traps antimicrobial actives to form a protective film on surfaces. The actives initially kill 99.99% of bacteria and viruses and go on to deliver 24-hour protection and peace of mind to consumers while ensuring excellent shine and a residue-free finish.

The product is supported by a full microbiological test data pack including efficacy against Coronavirus, Influenza A (H1N1) and Rotavirus in just 60 seconds, tested to UK and European standard test methods. It is compliant with the European Biocidal Products Regulation and can be used safely in a multitude of environments.

The business says that the test results will give its customers and end-users more confidence in which products on the market are proven to be effective.

Rick Hayman, Managing Director of Byotrol’s Professional Sales Division, said: “Many organisations and distribution channels have expressed concern over the mysticism of claims made by suppliers in the disinfection market. This latest test development will provide the necessary assurance to those organisations seeking proof of residual efficacy against viruses and other micro-organisms, whilst protecting their stakeholders as lockdown relaxes in the UK.”

For more information contact us on 01732 763555 or by email technical@medi-mark.co.uk

Medimark Scientific Terms and Conditions 2020-21

​Medimark Scientific Terms and Conditions of Sale - 2021

1) General
a. Unless otherwise expressly agreed in writing by a Director [or authorised executive] of the Company all goods are sold upon the following Terms and Conditions and no agent or representative of the Company has any authority to vary or omit these Terms and Conditions or any of them. Any Terms and Conditions printed on the buyer’s order forms or in correspondence or elsewhere or implied by trade, custom, practice or course of dealing are binding only insofar as they are not at variance with these Terms and Conditions and they have been specifically agreed to in writing by a Director [or authorised executive] of the company.

2) Quotations and Acceptance

a. Quotations issued by the Company whether verbally or in writing do not constitute offers and the Company reserves the right to withdraw or revise the same at any time prior to the Company’s acceptance of the buyer’s order.

b. The Company reserves the right at any time to refuse to accept orders and cancel any incomplete orders or to suspend delivery, due to circumstances beyond its control.

3) Prices

a. The prices shown in our price lists are correct at the time of printing but are subject to alteration without notice.

b. The prices payable for the goods shall be those that pertain at the time of order.

c. An administration fee of £5 will be added to any order under the value of £25

d. Unless otherwise specified, prices are exclusive of, carriage, VAT and any other duty or tax payable by the buyer, which shall be added to the price.

4) Delivery

a. The Company will use all reasonable endeavors to deliver at the time stated but delivery dates shall be regarded as estimates only and not of any contractual effect. The Company shall not be liable for any delay occasioned by any cause whatsoever beyond the Company’s control.

b. In the case of delivery of goods by installments, the buyer will not be entitled to treat the delivery of faulty goods in any one installment or the late delivery or non-delivery of any one installment as a repudiation of the whole contract.

c. The costs of carriage will be charged to the buyer on the invoice for the goods at the time of dispatch.

d. Deliveries cannot be made to PO Boxes as all goods must be signed for. Please advise of any restrictions to the delivery address at the time of order. Goods will be delivered between the hours of 08.00hrs & 18.00hrs

e. Economy delivery is charged at £13.75 up to 20kg + 28 pence per kg thereafter but may be subject to change from time to time

f. Next Day delivery subject to hazards classification compliance is charged at £18.75 up to 20kg + 32 pence per kg thereafter but may be subject to change from time to time

g. Deliveries to the Highlands and Islands are subject to charging at the prevailing rate – please note restrictions may apply and these will be advised on each individual order placed.

h. Deliveries of 200 litre and 1000 litre bulk products are subject to quotation and costs may vary dependent on quantity and location

5) Risk and Title to Goods

a. The risk in the goods passes to the buyer upon delivery but property in the goods remains vested in the Company and shall only pass from the Company to the buyer upon full payment being made by the buyer of all sums due on whatsoever account or grounds to the Company from the buyer. In the event of the goods being sold by the buyer in such manner as to pass to a third party a valid title to the goods, whilst any such sums are due as aforesaid, the buyer shall be the trustee for the Company of the proceeds of such sale or to the claim for such proceeds and the buyer shall place such proceeds in a separate bank account. The Company’s rights under this sub-clause (a) shall attach to the proceeds of such sale. Nothing herein shall constitute the buyer the agent of the Company for the purposes of any such sub-sale.

b. The buyer agrees that prior to full payment being made as aforesaid, the Company may at any time repossess the goods and enter upon the buyer’s premises and remove the goods there from (and dispose of the same in any manner it may decide) and that prior to such payment the buyer shall keep such goods as fiduciary agent and bailee and separate and identifiable for this purpose.

6) Payment

a. Payment of invoices shall unless otherwise agreed in writing be made in full without any deduction or set-off by the due date stated on the invoice.

b. Failure to make due payment in respect of any deliveries or instalments under this or any other contract between the buyer and the Company shall entitle the Company to delay, suspend or cancel deliveries in whole or in part at its option.

c. Any extension of credit allowed to the buyer may be changed or withdrawn at any time. Any credit accounts are payable 30 days from invoice date.

d. Payment by debit card and credit card are accepted with the exception of American Express

e. Account Terms are offered subject to satisfactory credit references.

f. If payment is not made in full by the due date stated on the invoice:-

i. That under the terms of the Late Payment of Commercial Debts (Interest) Act 1998 and the Late Payment of Commercial Debts Regulations 2002, the company have the right to claim interest and compensation for late payments at the rate of 8%above the Bank of England base rate (such interest to accrue on a day-to-day basis from the due date for payment until receipt by the Company of the full amount whether before or after any judgement). The company also has the right to claim reasonable third party debt recovery costs and the right to challenge contractual terms that do not provide a substantial remedy against late payments; and

ii. The buyer shall indemnify the Company against all costs and expenses (including any legal costs and expenses on a full indemnity basis) incurred or sustained by the Company in recovering sums due or in exercising its rights pursuant to Clause 5, in each case without prejudice to any other rights or remedies available to the Company.

iii. Payment shall be due whether or not property in the goods has passed by virtue of Clause 5 above and the Company shall (without prejudice to any other right or remedy) accordingly be entitled to sue for the price once the same is due even if property in the goods has not passed.

7) Data Protection Notice

a. Data relating to the Data Subject (Individuals who are the subjects of Personal Data and whose Data is processed by the Data Controller) will be processed by the Data Controllers (A person or organization which either alone or jointly or in common with other persons determines the purposes for which and the manner in which any Personal Data of the Data Subjects are processed) and will be held securely in confidence and processed for the purpose of carrying out the business of the Data Controllers and associates activities such as insurance, risk assessment and other related activities (“Activities).

b. The Data Controller may consult with and disclose the Data Subject’s Data to third parties such as insurers, credit insurers, credit reference agencies and other carefully selected parties (“Third Parties”) who may process the Data also as Data Controllers for the purpose of carrying out the Activities for any business applications made directly or indirectly to the Data Controllers by the Data Subject now or in the future. The Data Controllers may also receive Data on the Data Subject from the Third Parties. The Data will be processed both within and outside the European Economic Area.

c. The Data Subject can write to the Data Controller:

i. If the Data Subject does not have a contractual relationship with the Data Controllers and are objecting to the processing as setout above.

ii. The Data Subject requires access to their data held by the Data Controller.

iii. The Data subject requires details of any third-party data controllers who also process the Data Subjects Data.

8) Bank Funding, Invoice Discounting, Factoring

a. Where the customer uses banking facilities or factoring or an invoice discounting company which involves the selling of debtors or using debtors as security, the customer must notify the factoring or invoice discounting company of the Company’s interest in the goods and specifically that title in the goods has not passed until the invoice has been paid in full, as set out in 5 above.

9) Liability

a. The buyer shall inspect the goods upon delivery. The Company will make good at its option by credit or replacement any defects in the goods due solely to defective workmanship or materials which are notified in writing to the Company and, in the case of any defect discoverable upon reasonable examination, such notification must be made within three days from the date of delivery and, in the case of any defect not discoverable upon reasonable examination, such notification must be made within fourteen days of the date such defect is actually discovered provided that :

i. The aforesaid obligations on the Company shall not extend to defects caused by willful damage, negligence (other than by employees or agents of the Company), incorrect storage or application, movement, installation or defects caused by fair wear and tear;

ii. The aforesaid obligations on the Company shall in any event only apply for a period of twelve months from the date of delivery.

b. Save as herein set out and for liability for death or personal injury resulting from negligence on the part of the Company and save for breach of the seller’s statutory implied undertakings as to title, all express or implied conditions, representations or warrantees as to description, quality or fitness of the goods or otherwise are expressly excluded.

c. Save for liability for death or personal injury resulting from negligence of the Company, the Company’s aggregate liability under any one claim or under the total of all claims arising from any one act or default of the Company howsoever such a claim or claims arise (be it by negligence, breach of contract, misrepresentation or otherwise) shall in no circumstances exceed £50,000.00 or such greater figure as is from time to time the limit of liability laid down by the Company’s insurers in respect of such claims PROVIDED THAT the Company shall not be liable for any consequential or indirect loss or loss of profits or contract whatsoever(whether arising by the Company’s negligence or otherwise).

10) Force Majeure

a. The Company shall not be liable to the buyer for any loss or damage which may be suffered by the buyer as a direct or indirect result of the supply of goods by the Company being prevented, hindered, delayed or rendered uneconomic by reason of circumstances or events beyond the Company’s control including but not limited to Act of God, war, riot, strike, lock-out, trade dispute or labour disturbance, accident, break-down of plant or machinery, fire, flood, storm, difficulty of increased expense in obtaining workmen, materials or transport or other circumstances affecting the supply of goods or raw materials therefore by the Company’s normal source of supply or the manufacture of the goods by the Company’s normal means or the delivery of the goods by the Company’s normal route or means of delivery.

11) Legal Interpretation

a. Any agreement to which these Terms and Conditions apply shall be governed and construed in accordance with English Law and any dispute arising out of or in connection with such agreement shall be determined by the English Courts.

12) Severance and Waiver

a. In the event of any part of these Conditions being ineffective for any reason, the remainder thereof shall constitute the Conditions binding upon the parties.

b. Failure or neglect by the Company to enforce at any time any of the provisions hereof shall not be construed as nor be deemed to be a waiver of the Company’s rights hereunder nor shall such failure or neglect in any way affect the validity of the whole or any part of these Terms and Conditions and the Company’s right to take subsequent action shall not be prejudiced thereby.

13) Returns Policy

a. We are committed to selling high-quality products we hope you’ll enjoy the benefits of them but we also know that, for one reason or another, there may be a time when you need to exchange or return something that you have bought. Please make sure that you check your items carefully within 24hrs of delivery and also before they are used. We also recommend that you keep your order confirmation and the delivery packaging, as you might need it as proof of purchase in the event of any after-sales queries. We know that you will be pleased with your purchases from Medimark Scientific Ltd but if you do need to return anything to us the following policy will assist you.

b. Items Damaged in Transit - If any items were damaged in transit, we ask that you report it to us within 48hrs. If the items are visibly damaged on receipt, it is best to sign the carrier’s delivery note accordingly or refuse the delivery. By signing for the goods you are taking ownership and responsibility for their quality. Items should be returned in their original packaging complete with all accessories and documentation. Once received back into our warehouse, we will issue a replacement and issue a credit to your account. A new invoice will be raised for the replacement goods.

c. Items Faulty on Arrival / Incorrect Items Delivered - If your items are faulty or you have been delivered items that you did not order or have received the incorrect items, you have 7 days in which to inform us. Items should be returned in their original packaging complete with all accessories and documentation. Once we have verified the fault, we will issue a replacement and issue a credit to your account. A new invoice will be raised for the replacement goods. We thoroughly test and inspect all returned items, and if a returned item is found not to be faulty by our technicians you will be liable for the return carriage plus administration costs and restocking fees. A breakdown of these will be explained to you when you notify us of a return.

d. Items Faulty in Warranty Period - If any of your purchases develop a fault, and it’s more than 28 calendar days since receipt, then provided your item is within its warranty period, you are entitled to a warranty repair or replacement (subject to manufacturers advice). In some cases, manufacturers provide a specialist full on-site service and/or telephone help facility for your convenience which we recommend you use in order to correct the fault quickly. For business customers, all warranty repairs after 28 days of receipt are referred directly to the manufacturer (unless otherwise stated).

e. General - Any items reported or advised outside of the time restraints advised above cannot be returned or replaced.

MEDIMARK transitions to EC Certificate with SGS

​Following the decision by LRQA to withdraw from supporting medical device registrations, Medimark Scientific successfully engaged with SGS to accredit the company under ISO9001:2015 (completed on 19th February 2020).

Subsequently EC Certification followed from 24th April 2020 by SGS Belgium and then ISO13485:2016 from 6th May 2020.

Certificates are available upon request and further details can be obtained from Regulatory@medi-mark.co.uk .

INTERVIEWS WITH OUR GROUP CEO

Following interest in our company’s profile during the COVID outbreak and following the acquisition of Medimark Scientific, David Traynor (CEO of parent company Byotrol PLC) speaks with both Charlie Gibson of Core Finance and Andrew Scott of Proactive.

Follow the links to the interviews here: -

https://www.youtube.com/watch?v=BlfpRX_ivmc

https://www.proactiveinvestors.co.uk/companies/news/920054/byotrol-ceo-says-crisis-has-given-them-a-purpose-and-they-re-seeing—extraordinary—demand-920054.html

STATEMENT REGARDING OPPORTUNISTIC PROFITEERING

There have been multiple reports of hand sanitisers and other disinfectant products being sold on Amazon, Ebay and by companies at significantly elevated prices, driven by opportunistic profiteering. Trading Standards and the Government has already made statements regarding task forces to crack down on this practice and some countries have set limits on the prices of certain products.

Medimark Scientific takes a moral and ethical approach to pricing and sale of our products and we strongly distance ourselves from any company that would use this crisis for the purposes of profiteering.

Rest assured that the price you pay today is unchanged through this crisis!

For more information and assistance please call 01732 763555.

MEDICA 2019 - expanding the distribution network

Following the success of our recent International Distributor Meeting, Medimark Scientific will be again attending MEDICA 2019.in Dusseldorf from 18th to 21st November 2019.

Medimark Scientific operates within human health, animal health, laboratory, life science, emergency service and associated industries in the UK and also keen to support our EU and International distributors as well as building and growing our presence overseas. Our portfolio of class I, class IIa and class IIb registered medical devices includes: -

CHEMGENE HOCL2000 Sporicidal Surface Disinfectant (class IIa)

CHEMGENE HLD4H Surface Disinfectant in concentrate, Wipes and RTU Trigger Spray (class IIa)

REPROZYME CE Enzymatic Instrument Cleaning Solution (class I)

ULTRA P Instrument Cleaner for stainless steel instruments (class I)

ULTRA SSC Stainless Steel Conditioner for instruments and devices in need of restoration

REPRODIS HLD4i Instrument Disinfectant (class IIb)

INVIRTU Alcohol Free Hand Sanitising Foam with residual efficacy

Our attendance at MEDICA this year will be with the support of the Association of British Healthcare Industries (ABHI) and we can found in their pavilion located in hall 16, our stand number is 16K17-2

for more information or to arrange a meeting on our stand please email export@medi-mark.co.uk

Medimark Scientific sets its sights on the Dental market

Medimark Scientific supplies disinfectants and and cleaning products to the human health, laboratory, life science, environmental, emergency service and animal health markets for many years.

As an ISO9001:2015 an ISO13485:2016 accredited manufacturer of such products, our portfolio of class I and IIa medical device registered products are ideally suited for the dental industry and certain key products are already well known and used in this market, such as Ultra P Instrument Cleaner. Similar to other industries the Dental industry is comprised of independent practitioners and larger groups that single source their products from larger supply chain providers. Medimark Scientific is well versed in supporting larger groups with preferred supplier agreements as well as meeting the needs of individual practices.

This year we will be attending the BDIA Dental Showcase, held at the NEC Birmingham from 17th to 19th October - see us at stand P72.

Our product portfolio on display will include: -

CHEMGENE HOCL2000 Sporicidal Surface Disinfectant (class IIa)

CHEMGENE HLD4H Surface Disinfectant in concentrate, Wipes and RTU Trigger Spray (class IIa)

REPROZYME CE Enzymatic Instrument Cleaning Solution (class I)

ULTRA P Instrument Cleaner for stainless steel instruments (class I)

ULTRA SSC Stainless Steel Conditioner for instruments and devices in need of restoration

INVIRTU Alcohol Free Hand Sanitising Foam with residual efficacy

For more information, please email technical@medi-mark.co.uk

HLD4 formulation meets further benchmarks in testing…

Medimark Scientific continues to build its microbiological test portfolio for its HLD4 formulation.

Recent testing undertaken demonstrates efficacy in 5 minutes against Murine Norovirus, Adenovirus and also under EN13610:2002 against Lactococcus lactis to be virucidal against Bacteriophages.

Further testing is underway and will be reported upon in due course, but for more information please email technical@medi-mark.co.uk

6 modules of Accredited CPD

Medimark Scientific are proud to announce we have recently achieved accredited CPD Status with the CPD Standards Office.

To achieve the accreditation Medimark Scientific has undergone a rigorous assessment process that focuses on the development and delivery of our training including our educational authority, how we collect and utilise our delegate feedback and ensure our content is kept up to date.

Now we have achieved this accreditation and status as an accredited CPD Provider, we are committed to working hard to maintain, and exceed, the excellent standard we have already set.

For more information on our Accredited CPD please email training@medi-mark.co.uk

Effervescent Chlorine tablets remain a potent tool in managing Ebola outbreaks such as in DR Congo

The World Health Organisation has referenced the use of Chlorine in its Q&A and guidance information concerning water, sanitation and hygiene since publication in October 2014. For more information, follow the WHO link below:

https://www.who.int/csr/resources/publications/ebola/water-sanitation-hygiene/en/

Chlorine solution has been indicated to use in the washing of reusable PPE as well as surfaces that may have come into contact with body fluids, and areas contaminated with blood and other body fluids, and to be used in the final soaking of soiled bed linen after removal of solid decontamination, and detergent washing.In tablet form the products are easy to store securely, easy to use and have a 5 year shelf life and so ideal for immediate use and as a longer term emergency supply easily deployed for outbreak use.

For more information on our CHEMGENE NaDCC Chlorine tablets, please see our product page - http://medi-mark.co.uk/products/product/chemgene-nadcc-effervescent-chlorine-tablets or contact export@medi-mark.co.uk

ISO13485:2016

Following an all involved team effort and successful audit by LRQA, Medimark Scientific has not only maintained their existing accreditation to ISO9001:2015 but has also transitioned to the ISO13485:2016 standard Quality Management Systems for medical devices.

Medimark Scientific offer a range of class I, IIa and IIb registered devices for instrument / device cleaning, medical device surface disinfection and for disinfection of non-surgically invasive device.

For more information CLICK HERE

Efficacy against Murine Norovirus

CHEMGENE HLD4 has been re-tested to be effective against Murine Norovirus at 1:100 under EN14476.

Combined with its broad range efficacy against bacteria, yeasts and other viruses in dirty conditions, CHEMGENE HLD4H is ideal for home use and community health Primary Care applications as well as its recommended use for professional applications in hospitals, dentists and other clinical areas.

For wholesale enquiries and further information please email info@medi-mark.co.uk

Regulatory Impact of Brexit on Medical Devices

Marking of medical devices in accordance with the requirements of European Council Directive 93/42/EEC as amended permits the sale of CE marked product throughout Europe.

Medimark Scientific Limited are certified by Lloyds Register (LR) in the United Kingdom for the manufacture and distribution of CE marked medical device disinfectants throughout Europe. Such certification is denoted by displaying the CE mark and Lloyds Register’s UK notified body number 0088 on the product label.

The impact of the process known as Brexit on CE marked products manufactured by Medimark Scientific is as yet unclear due to the lack of information and planning that is forthcoming from our Government however, there are a number of potential scenarios that are being considered. Any form of Brexit which does not include plans to allow UK Notified Bodies to continue to provide their clients with CE marking services could directly lead to the risk of patients’ lives in the UK and EU. Our Notified Body believes it is therefore extremely likely that the UK Government and the EU Commission will forge a suitable agreement with the EU27 to prevent this from happening.

Worst Case Scenario – No Deal/Hard Brexit

To maintain our ability to place product on the market in the event of a no deal or hard Brexit, we are required to use a European recognised Notified Body. Our UK Notified body has submitted an application to the Dutch Competent Authority (Inspectie Gezondheidszorg en Jeugd, IGJ) for appointment as a Notified Body in the Netherlands. This will enable them to provide identical services to those they currently provide through their UK Notified Body with what is expected to be a reasonably straightforward process.

If the LR application to the Netherlands is not approved in time and in, what they view as the highly unlikely event of a hard Brexit, then they would be unable to provide Notified Body services for products entering the EU27 markets and as such, current LR issues EC certificates would cease to be valid with effect from the withdrawal date (1st November 2019 00:00 hrs CET). The implications of such a situation are unprecedented.

Therefore, in the worst-case scenario of no deal or a hard Brexit our current EC Certificate will become void on the date at which the UK leaves the EU (31st October 2019). This will result in us not being able to place product on the market until such times as Medimark Scientific Ltd has an EC Certificate from a European Notified Body.

Soft Brexit

In the event that the proposed deal is struck, it is our understanding that a ‘Soft Brexit’ will include an implementation period in which the conformity assessment regime remains unchanged. One possible outcome is that the mutual recognition of Notified Bodies will be included in the proposed transition agreement, covering the period until December 2020 and may also include the possibility of a permanent mutual recognition scheme forming part of the final agreement however, this is yet to be seen. In such a scenario, our existing EC certificate, issued by LR (UK) will continue to be recognised in the EU, in at least the short term, allowing for a period of time to understand what new arrangements are required (if any).

What this could mean for you?

We are continuously liaising with our Notified Body and Government Departments to understand the situation as it unfolds and are putting measures in place to mitigate risks where possible. Existing product that is already in the market, including stock which has been sold to distributors, will continue to be supported under the original CE mark. We feel it necessary to warn customers, particularly those outside of the UK that there may be a period of time whereby Medimark Limited may not be able to directly supply products under our existing CE mark and there may be a delay in obtaining a new CE mark from which is directly linked to the approval of Lloyds Register in the Netherlands and the administration transfer to them. As such we are advising customers to review their current stock levels and order as appropriate in advance of the 1st November 2019 00:00 deadline.

We will endeavor to keep all customers informed of updates as and when they are available. In the meantime, the management team at Medimark Scientific Ltd are on hand to answer any questions that customers may have.

Regulatory Department
19.12.2018 (updated 31st May 2019)

Acquisition of UK infection control company Medimark Scientific Limited

Byotrol plc, the AIM listed anti-microbial hygiene company, is pleased to announce the acquisition of Medimark Scientific Limited (“Medimark”) a leading provider of biocide-based infection control products into the animal and human healthcare markets.

Medimark is a profitable and growing business which has a broad sales, marketing and distribution expertise. Medimark sells infection control products used on surfaces, instruments and hands for the Animal Health, Human Health, Laboratory, Environment and Retail markets. The company is based in Sevenoaks, Kent, and is ISO9001 quality registered with supporting registration under the Medical Device Directive

There is an existing and long-standing relationship already in place between the two companies – Byotrol is currently a white label supplier of hand sanitisers to Medimark, which it sells under its Esense brand.

Highlights:

  • Immediately provides Byotrol with greater scale than could be achieved through current rates of organic growth. Medimark is profitable and cash generative and fits extremely well with Byotrol’s existing products and technology.
  • Highly complementary acquisition, offering extensive sales, marketing and distribution expertise in Byotrol’s core markets. Specific complementary with Byotrol’s Professional and Petcare businesses with significant synergies expected over time, including: enhanced distribution of Byotrol technologies to Medimark customers, in the UK and overseas, boosting economies of scale, distribution and market segment expertise, highly experienced, well-connected and resilient sales team and sales support and introduction of stronger disinfectant technologies to Byotrol portfolio including a proprietary sporicidal formulation
  • Doubles workforce, creating immediate critical mass with cost synergies available from bringing Medimark technical work in house.
  • Executive management staying with the combined business for the earnout and beyond, with incentives closely aligned with Byotrol shareholders.


Commenting on the
acquisition, John Langlands, Byotrol Chairman, said:

“We are delighted to have concluded the acquisition of Medimark and we welcome its directors, employees, customers and stakeholders to Byotrol. The fit between the two companies is remarkably strong with Medimark’s excellent sales and marketing capabilities dovetailing very well with our technical expertise. We also see more opportunities to take the combined group’s infection control products into consumer markets. Our enlarged operations will now be offering cutting-edge infection control products to more customers in our jointly-targeted markets with improved propositions. We have a strong balance sheet and are confident that the combination of the two companies will bring Byotrol to critical mass with the resources to deliver sustained growth and profitability.“


Rick Hayman, the MD and
major shareholder of Medimark, added:

“Joining forces with Byotrol is a very exciting step forward for the Medimark team, enabling us to take our business to a new level. With their technical expertise and our combined commercial and sales experience skills, we see the two companies as an excellent fit. We very much look forward to pursuing the market opportunities together with the Byotrol team.”

FOR MORE INFORMATION PLEASE CONTACT

PR@medi-mark.co.uk

Where “DEFRA APPROVAL” Is Required

The use of a “DEFRA APPROVED” product and its relevance to companion animal health organisations has often been confusing and exploited by certain competitors to sell their products.

The DEFRA protocol is established to identify products that can be used in the event of a notifiable disease outbreak under one of the five orders, being Diseases of General Orders, Poultry Order, Swine Vesicular Disease, Foot and Mouth Disease and TB. However, a “DEFRA Approved” product is ONLY required in the event an outbreak of one of such diseases and even then a recommended disinfectant under the relevant order should be used. Generally, products on the Approved Disinfectants list are designed for agricultural environments and designed to work in cold and extremely soiled environments, unlike most companion animal establishments.

Some commonly available companion animal disinfectants do have DEFRA Approval, but we believe that it is impractical to provide DEFRA Approval for all fragrance varieties and all disease orders, since products of our type (made for safe use around animals) generally pass at only high dilutions under DEFRA testing, such as 1:2 - 1:10. We regard these dilutions for companion animal health as impractical for several reasons: -
Instead and where ther is the rarity of a Notifiable Disease Outbreak, we recommend a product that is specially designed for such application. ANIGENE NaDCC has been tested across the majority of Notifiable Diseases at a dilution of between 1:317 and 1:953, with General Orders at 1:360. Additionally, this product is effective against Giardia Lambliaand is recommended as a periodic Deep Clean product or as an economic disinfectant in the event of a notifiable disease outbreak.

  • Using a product at 1:2 - 1:10 (30% - 10%) disinfectant to water ratio would be very expensive
  • Using a product at these dilutions would make cleaning very difficult
  • exceptional foam levels, residue build up, sticky floors, excessive rinsing required
  • There is a potential risk to staff and animals from contact with concentrated chemicals

INTERESTED IN DISTRIBUTING OUR PRODUCTS?

INTERESTED IN DISTRIBUTING OUR PRODUCTS?

WHOLESALE AND EXPORT ENQUIRIES WELCOME!

Join the war against MRSA, E.coli, Coronavirus, Hepatitis, etc. We have opportunities for companies or business motivated individuals to develop exclusive Regional Distributorships and agents for high level infection control and hygiene products into the Human Health, Environmental and Animal Health sectors. We are a UK manufacturing company with over twenty years successful track record and recognised branding in the industry.

Please email us distributors@medichem.co.uk for more information and to register your interest.